ImmunityBio is on a Mission

David Sachs joined ImmunityBio as its Chief Financial Officer in July 2019. He brings over two decades of operating, development and investing experience as a finance, private equity, venture capital and investment banking executive. Previously, Sachs served as CFO for several NantWorks subsidiaries, including NantHealth (Nasdaq: NH) and Integrity Healthcare. He also served as a principal and executive at NantCapital, acting as a member of the investment committee. Prior to his roles with NantWorks, Sachs was an investment banker for Bank of America Merrill Lynch and held senior operating roles at Abraxis BioScience and Celgene (Now Bristol Myers Squibb). He currently serves as a Director of Airstrip Technologies, Inc., Packetfabric, Inc., and the Chan Soon-Shiong Medical Center at Windber. Sachs received his MBA in Finance and Strategy from the UCLA Anderson School of Management and his BA in Economics from the University of California at Los Angeles.

Dr. Lennie Sender joined ImmunityBio as its Chief Operating Officer in March 2020, having previously served as Senior Vice President of Medical Affairs at NantKwest. Prior to joining NantKwest, he served as the Medical Director of the Hyundai Cancer Institute at Children’s Hospital in Orange County, California, and also has served as Medical Director of Clinical Oncology at the University of California’s National Cancer Institute-designated Chao Family Comprehensive Cancer Center. Dr. Sender is an accomplished blood and marrow stem cell transplant surgeon and oncologist who received his medical degree from the University of Witwatersrand in Johannesburg, South Africa and subsequently trained in pediatrics at the University of California, Irvine and in pediatric hematology-oncology at Children’s Hospital Los Angeles. He has previously served as the President of the Society for Adolescent and Young Adult Oncology (SAYAO) and has served as Editor-in-Chief of the Journal of Adolescent and Young Adult Oncology (JAYAO).

Dr. Sandeep Reddy joined ImmunityBio as Chief Medical Officer in August 2020 after serving as Chief Medical Officer of NantHealth. Previously, he was Chief Medical Officer of Caris Life Sciences. Previously, Dr. Reddy was Chief of Staff at Los Alamitos Medical Center, actively practicing clinical hematology and oncology, while holding an adjunct faculty position at the Geffen/UCLA School of Medicine as a clinical instructor at Harbor-UCLA Medical Center.His executive and medical oversight has produced over 100 abstracts at major medical conferences and over 30 peer-reviewed publications in the field of precision medicine and oncology since 2015. His medical training includes fellowship training in hematology and medical oncology and therapeutics research at City of Hope, and Internal Medicine residency at Harbor-UCLA Medical Center. Dr. Reddy received his MD from the Geffen/UCLA School of Medicine after receiving his BS in biomedical sciences at the University of California, Riverside.

Sarah is responsible for developing ImmunityBio’s communications strategy, overseeing corporate and public affairs, branding, media relations, and internal communications. In addition, she is responsible for developing the strategic patient advocacy program for the company’s oncology pipeline and future commercial products. She joined ImmunityBio (formerly NantKwest) in 2019, where she developed a communications and reputation strategy supporting the company’s growth and value creation.

During her 20-year career as a senior corporate communications and marketing executive, Sarah has held leadership roles at a variety of private and public companies in the biotech, technology and energy sectors. Sarah also served as a SVP and Partner at FleishmanHillard, where she managed teams supporting investor relations, financial communications and marketing for the global agency’s clients. She holds a B.S. in Journalism from Ohio University.

Regan Lauer joined ImmunityBio as its Chief Accounting Officer in November 2021. She has over 20 years of experience as a senior financial executive in the biotechnology and financial services industries. Prior to joining ImmunityBio she was the Corporate Vice President of Accounting at Progenity, Inc. (now Biora Therapeutics) where she helped the company successfully complete an initial public offering in 2020. Lauer also served as the Chief Financial Officer at Silvergate Capital Corporation and has held many other senior financial management positions including Principal Accounting Officer at First PacTrust Bancorp, Inc. (now Banc of California). Lauer began her career as an auditor with the accounting firm of Deloitte and holds a Bachelor’s degree in accounting from Saint Louis University.

Dr. Manju Saxena is the Vice President of Product Development, and oversees the company’s process and analytical development activities for cell therapy program. Dr. Saxena is a scientific leader with over 30 years of experience directing projects from discovery to development in the areas of oncology, metabolic, immune disorders, and infectious diseases. Prior to joining NantKwest, she managed discovery and bioanalytical projects at Intertek’s Immunochemistry Centre of Excellence, Tandem labs, Amylin Pharmaceuticals, and Kirin Pharma USA. She has authored more than 50 peer reviewed articles and book chapters. Dr. Saxena received M.Phil and Ph.D. from University of Delhi.

Bruce Brown, M.D. is Senior Vice President, Medical Affairs, reporting to the CEO. He is responsible for all medical affairs activities in bladder cancer as well as other tumor types, including overseeing the field medical activities. Dr. Brown also provides leadership for ImmunityBio’s ongoing trial efforts. He has extensive pharmaceutical industry experience in medical affairs and clinical development and the majority of this experience has been in bladder cancer and prostate cancer. Prior to ImmunityBio, Dr. Brown held leadership positions at Astellas, Dendreon, Myovant and Aura Biosciences. He is a Board Certified urologist and practiced urology in the Chicago area before joining the pharmaceutical industry. Dr. Brown received his undergraduate degree from Stanford University and his medical degree from the University of Illinois College of Medicine.

Enrique Diloné, Ph.D. is Chief Technology Officer, reporting directly to the CEO. In this role he is responsible for ImmunityBio’s worldwide manufacturing capacity and operations – both company-owned and contract manufacturing – as well as quality assurance, quality control, supply chain and project management. Dr. Diloné has more than 30 years of pharmaceutical manufacturing expertise and has held key leadership positions at Prothelia, Amicus Therapeutics, NovaDel Pharma, OSI Pharmaceuticals and Wyeth. During his career, he contributed to the licensure of several commercial products, including Galafold®, ZolpiMist®, and MACUGEN®, as well as had key roles in the development and manufacture of several other clinical products. Dr. Diloné received his BA in chemistry from New York University and earned an MS and Ph.D. in chemistry from Seton Hall University. He is also a graduate of the General Management Program at Harvard Business School.

Charles Garlisi, Ph.D. is Senior Vice President, Regulatory Affairs, reporting directly to the CEO. In this role he is responsible for ImmunityBio’s worldwide regulatory activities. Dr. Garlisi has more than 30 years of experience in the pharmaceutical industry with expertise in discovery and regulatory areas. Prior to joining ImmunityBio, he held leadership positions at Schering-Plough Research Institute, Merck Research Laboratories, and Hurley Consulting Associates. During his career, he has contributed to the development of several commercial products including Asmanex® and Capvaxive®. Dr. Garlisi received his BS in biology from St. Francis College, NY and earned a Ph.D. in biochemistry from The Pennsylvania State University.

Emily Arison joined ImmunityBio as its Senior Vice President of Human Resources in July 2021. She has 20+ years’ experience as a senior human resources executive in the healthcare and biotechnology industries. Prior to joining ImmunityBio she was the Corporate Vice President of Human Resources and Facilities at SCAN Health Plan where she helped the company grow from $500m to $3.5b. Emily holds a Bachelor’s degree in Sociology from University of California, Santa Barbara and Masters of Art in Sociology from University of Nevada, Reno

As Vice President of Product Development for the company’s vaccine sciences program, Elizabeth Gabitzsch is responsible for the development of novel vaccines. Gabitzsch has extensive experience in the process, product development, and manufacturing of ImmunityBio’s proprietary vector technology and her responsibilities include everything from strategy development to day-to-day program management. Prior to joining Etubics, which was acquired by ImmunityBio, she was with the Centers for Disease Control and Prevention (CDC) in the Division of Vector-borne and Infectious Diseases where she was a recipient of an Oak Ridge Institute of Science fellowship. Gabitzsch received academic training in microbiology, chemistry and immunology at Colorado State University. Her research has focused on virology, vaccinology and immunotherapy.

Matthew Hilman joined ImmunityBio in 2024 to lead the U.S. commercial team and all aspects of the company’s commercial launch strategy. He brings deep expertise in the marketing of hematology, oncology, and urologic oncology assets to this key position. Matthew’s strategy hinges on four leadership principles: collaboration, empowerment, transparency, and accountability, which have helped the company’s sales team achieve success in a short time in highly competitive marketplace. Earlier in his career, Matthew drove the rapid adoption of novel urologic oncology therapies and led the development of go-to-market strategies for oncology assets in pre-approval stages at multiple companies. An 8-time President’s Club award winner, he holds a B.S. in Marketing and Management from York College of Pennsylvania.